Simulations PlusFRA:SD3 67 Market Cap is €326.47 Mil as of Jul. 05, 2026. GuruFocus rates FRA:SD3 with a GF Score™ of 67/100 and a GF Value™ of €32.93 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 692 Healthcare Providers & Services companies, Simulations Plus ranks better than 67.2% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Simulations Plus's share price for the quarter that ended in Feb. 2026 was €10.1. Simulations Plus's Shares Outstanding (EOP) for the quarter that ended in Feb. 2026 was 20.21 Mil. Therefore, Simulations Plus's market cap for the quarter that ended in Feb. 2026 was €204.07 Mil.
Simulations Plus's quarterly market cap
increased
from Aug. 2025 (€745.07 Mil) to Nov. 2025 (€745.44 Mil) but then
declined
from Nov. 2025 (€745.44 Mil) to Feb. 2026 (€204.07 Mil).
Simulations Plus's annual market cap
stayed the same
from Aug. 2023 (€0.00 Mil) to Aug. 2024 (€0.00 Mil) but then
increased
from Aug. 2024 (€0.00 Mil) to Aug. 2025 (€745.07 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Simulations Plus's Enterprise Value for Today is €290.18 Mil.
Simulations Plus (FRA:SD3) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Simulations Plus Market Cap Related Terms
Simulations Plus Market Cap Historical Data
* Premium members only.
The historical data trend for Simulations Plus's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Simulations Plus's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simulations Plus Market Cap vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Simulations Plus's Market Cap distribution charts can be found below:
* The bar in red indicates where Simulations Plus's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Simulations Plus's Market Cap for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simulations Plus (FRA:SD3) has a Market Cap of €326.47 Mil as of Jul. 05, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Simulations Plus and its competitors. According to the industry distribution chart, Simulations Plus ranks #227 out of 692 companies in the Healthcare Providers & Services industry, placing it in the top 32.8%.
Is Simulations Plus' Market Cap too high?
Simulations Plus' current Market Cap is €326.47 Mil. Based on the distribution chart, Simulations Plus ranks #227 out of 692 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Simulations Plus has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Simulations Plus' Market Cap compare to TBRG and CARL?
According to the Healthcare Providers & Services industry distribution chart, Simulations Plus ranks #227 out of 692 companies for Market Cap. This puts Simulations Plus in the upper half of its industry. The industry median Market Cap is 98.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Healthcare Providers & Services company?
The median Market Cap among Healthcare Providers & Services companies is 98.30, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Simulations Plus and its competitors. For the Healthcare Providers & Services industry, the median Market Cap is 98.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simulations Plus's current Market Cap is €326.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simulations Plus stock overvalued right now?
Based on GuruFocus' analysis, Simulations Plus (FRA:SD3) is currently considered Significantly Undervalued. The stock's GF Value™ is €32.93, compared to a current price of €15.80 — trading 52% below its estimated fair value. The current Market Cap is €326.47 Mil. Simulations Plus' overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Simulations Plus (FRA:SD3), the current Market Cap is €326.47 Mil as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simulations Plus (FRA:SD3) Overvalued in 2026?
Based on GuruFocus' analysis, Simulations Plus stock appears to be undervalued.
The current stock price of €15.80 is trading 52% below its estimated GF Value™ of €32.93.
GuruFocus considers Simulations Plus to be Significantly Undervalued.
Key valuation signals for FRA:SD3:
Market Cap: €326.47 Mil
GF Value™: €32.93 vs. price of €15.80 (52% below fair value)
No single metric tells the full story. See the FRA:SD3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
67GF Score
Get the complete analysis for FRA:SD3
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:SD3 has been successfully added to your 
